CROI 2022: Lenacapavir in treatment-experienced participants, and as PrEP in macaques
1 March 2022. Related: Conference reports, Antiretrovirals.
Conference reports
CROI 2022: Fourth potential stem cell HIV cure – in a US woman using donor cord cells
1 March 2022. Related: Conference reports, Cure-related research.
CROI 2022: Strategies to suppress viral load off-ART with 3BNC117, 10-1074 and other bNAbs
1 March 2022. Related: Conference reports, Cure-related research.
CROI 2022: Targetting reservoir with ART + bNAb 3BNC117 + romidepsin maintained undetectable viral load off-ART for 3.7 years in one case
1 March 2022. Related: Conference reports, Cure-related research.
CROI 2022: Dual bNAb treatment maintains undetectable viral load off-ART in 44% of children in the Tatelo Study
1 March 2022. Related: Conference reports, Paediatric care, Cure-related research.
CROI 2022: AAV8-VRC07 vaccine generates new bNAb production in HIV positive people for up to three years
1 March 2022. Related: Conference reports, Cure-related research.
CROI 2022: No impact from high-dose vitamin D3 on reducing the HIV viral reservoir
1 March 2022. Related: Conference reports, Cure-related research.
CROI 2022: Higher maternal mortality and adverse birth outcomes among women with COVID-19 in Botswana
1 March 2022. Related: Conference reports, Women's health, Pregnancy.
CROI 2022: ANCHOR study reduces anal cancer by 57% and supports screening for people living with HIV
1 March 2022. Related: Conference reports, Cancer and HIV.
CROI 2022: Other studies on anal cancer
1 March 2022. Related: Conference reports, Cancer and HIV.
CROI 2022: Telomere shortening associated with TAF but not TDF in CHARTER study
1 March 2022. Related: Conference reports, Basic science and immunology, Ageing and life expectancy.
CROI 2022: Injectable PrEP: impressive results, new viral load monitoring – but price questions access
1 March 2022. Related: Conference reports, HIV prevention and transmission.
CROI 2022: Long-acting doravirine implants as PrEP to prevent vaginal HIV transmission in mouse study
1 March 2022. Related: Conference reports, HIV prevention and transmission.
CROI 2022: LEAP Workshop online: research into long-acting drugs
1 March 2022. Related: Conference reports, On the web.
CROI 2022 to only be virtual: programme online
7 February 2022. Related: Conference reports.
18th International European AIDS Conference (EACS 2021)
20 December 2021. Related: Conference reports.
EACS case study: how to diagnose HIV on PrEP – stopping PrEP or intensify to ART?
20 December 2021. Related: Conference reports, HIV prevention and transmission.
European AIDS Clinical Society honours Simon Collins for longstanding contribution to the field of HIV
20 December 2021. Related: Conference reports, Treatment advocacy.
18th International European AIDS Conference (EACS 2021)
30 November 2021. Related: Conference reports.
Lenacapavir: drug resistance after viral rebound in treatment experienced participants
30 November 2021. Related: Conference reports, Antiretrovirals, Drug resistance.
Implications of historical M184V on use of dual dolutegravir/lamivudine ART
30 November 2021. Related: Conference reports, Antiretrovirals, Drug resistance.
Stopping long-acting cabotegravir/rilpivirine: 1 in 5 trial participants didn’t restart oral ART within eight weeks
30 November 2021. Related: Conference reports, Antiretrovirals.
Islatravir plus doravirine dual ART: 144 week follow-up from phase 2 study
30 November 2021. Related: Conference reports, Antiretrovirals.
HIV-specific mental health services across the EU
30 November 2021. Related: Conference reports, Coinfections and complications.
18th International European AIDS Conference (EACS 2021)
31 October 2021. Related: Conference reports.
EACS 2021: a call for collaborations and for both HIV and COVID-19
31 October 2021. Related: Conference reports, Treatment strategies, HIV prevention and transmission.
Reduced responses to COVID-19 vaccines at low CD4 counts
31 October 2021. Related: Conference reports, COVID-19: HIV and COVID-19 coinfection, COVID-19.
EACS Guidelines: 11th edition (October 2021)
31 October 2021. Related: Conference reports, Guidelines.
Community “Respect my HIV” march: 30 October 2021 in London
31 October 2021. Related: Conference reports, Treatment advocacy.
11th IAS Conference on HIV Science (IAS 2021)
17 September 2021. Related: Conference reports.
IAS 2021 website now open access
17 September 2021. Related: Conference reports, On the web.
Substudies from the ODYSSEY trial: results July 2021
17 September 2021. Related: Conference reports, Paediatric care.
Trial design for next generation PrEP
17 September 2021. Related: Conference reports.
11th IAS Conference on HIV Science (IAS 2021)
1 August 2021. Related: Conference reports.
IAS 2021: lenacapavir studies show impressive results in naive, extensive drug resistance and potential as PrEP
1 August 2021. Related: Conference reports, Antiretrovirals.
IAS 2021: HIV pipeline drugs: CAB/RPV LA, fostemsavir, paediatric dolutegravir, lenacapavir, islatravir, MK-8507 and albuvirtide
1 August 2021. Related: Conference reports, Antiretrovirals.
IAS 2021: Proving efficacy of next generation PrEP: counterfactual controls in lenacapavir and islatravir studies
1 August 2021. Related: Conference reports, HIV prevention and transmission, Research studies.
IAS 2021: WHO report links HIV to 30% increased mortality from COVID-19: based on South African data
1 August 2021. Related: Conference reports, COVID-19: HIV and COVID-19 coinfection, COVID-19.
IAS 2021: New demands for better transgender heath care: No data no more
1 August 2021. Related: Conference reports, HIV prevention and transmission.
13th International Workshop on HIV Paediatrics 2021
1 August 2021. Related: Conference reports, Paediatric care.
Dolutegravir superior to standard-of-care in young children: results from the ODYSSEY trial
1 August 2021. Related: Conference reports, Paediatric care.
5th Joint BHIVA/BASHH Conference 2021
1 July 2021. Related: Conference reports.
Few vertical HIV transmissions in the UK but contributing factors remain associated with inequality
1 July 2021. Related: Conference reports, Pregnancy.
5th joint BHIVA/BASHH conference 2021
1 June 2021. Related: Conference reports.
Weight changes on ART and how to lose weight successfully
1 June 2021. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications, Nutrition.
Selected presentations at BHIVA: COVID-19, PrEP in the UK, community involvement and more…
1 June 2021. Related: Conference reports, COVID-19: transmission & prevention, COVID-19.
28th Conference on Retroviruses and Opportunistic Infections (CROI 2021) virtual
1 June 2021. Related: Conference reports.
No differences in outcomes among women with and without HIV with high-risk pregnancies and COVID-19
1 June 2021. Related: Conference reports, Pregnancy, COVID-19: pathogenesis, COVID-19.
Dolutegravir-based regimens safe and effective in pregnancy and postpartum
1 June 2021. Related: Conference reports, Pregnancy.
Dolutegravir superior to standard of care in children and adolescents: results from the ODYSSEY trial
1 June 2021. Related: Conference reports, Paediatric care.
Joint BHIVA/BASHH Spring Conference 2021
3 May 2021. Related: Conference reports.
BHIVA registry reports HIV is independently linked to worse presentation and outcomes from COVID-19
3 May 2021. Related: Conference reports, COVID-19: HIV and COVID-19 coinfection, COVID-19.
HIV is linked to higher mortality from COVID-19 compared to HIV negative: 60% of deaths were black ethnicity
3 May 2021. Related: Conference reports, COVID-19: HIV and COVID-19 coinfection, COVID-19.
Case-control study of HIV positive people hospitalised with COVID-19
3 May 2021. Related: Conference reports, COVID-19: HIV and COVID-19 coinfection, COVID-19.
28th Conference on Retroviruses on Opportunistic Infections (CROI 2021)
1 April 2021. Related: Conference reports.
CROI 2021: First results using capsid inhibitor lenacapavir against MDR HIV: potential for six-monthly ART and PrEP
1 April 2021. Related: Conference reports, Antiretrovirals.
CROI 2021: Pregnancy outcomes and weight gain with dolutegravir and TAF
1 April 2021. Related: Conference reports, Pregnancy.
CROI 2021: New compounds for prevention and treatment of COVID-19
1 April 2021. Related: Conference reports, COVID-19: investigational drugs, COVID-19.
Oral molnupiravir at higher dose reduces SARS-CoV-2 viral load at day five in small phase 2 study
1 April 2021. Related: Conference reports, COVID-19: investigational drugs, COVID-19.
Bamlanivimab prophylaxis reduces hospitalisation and mortality: results from phase 3 BLAZE-2 study
1 April 2021. Related: Conference reports, COVID-19: investigational drugs, COVID-19.
Dual Eli-Lilly mAb bamlanivimab and etesevimab reduces hospitalisation after single infusion: results from BLAZE-1 study
1 April 2021. Related: Conference reports, COVID-19: investigational drugs, COVID-19.
Dual Regeneron mAbs casirivimab with imdevimab reduce transmission: interim results from phase 3 study
1 April 2021. Related: Conference reports, COVID-19: investigational drugs, COVID-19.
CROI 2021: Presentations from the LEAP workshop 2021
1 April 2021. Related: Conference reports, Other news.
CROI 2021: Presentations on NATAP.org
1 April 2021. Related: Conference reports, Other news.
28th Conference on Retroviruses and Opportunistic Infections (CROI 2021)
12 March 2021. Related: Conference reports.